Navigation Links
Avandia Lawsuit Settlement News: 'No News is Bad News,' Says Plaintiffs

NEW YORK, April 5, 2011 /PRNewswire/ -- The latest news on the much publicized Avandia Settlement's is: there is no news.  After a Bloomberg report made public last summer that many of the Avandia suits were coming to a settlement range of approximately $86,000.00 per suit, no new news has come into the market.  This has left many suffering Avandia plaintiffs with more confusion -and concern- when they will actually get their settlement money.

This has led to many Avandia Plaintiffs to seek lawsuit funding in order to receive some cash to pay bills today, prior to getting their actual settlements.  Once industry that tracks the Avandia litigation is the "legal funding industry," where in March one funding company, (Legal-Bay LLC), announced a substantial rise in Avandia lawsuit cash advances.  

Dave Kole, CEO of, spoke about the recent developments, "most of our clients tell us the same thing, they are frustrated with the process.  They are confused because there has been no news in the marketplace about how much they will receive, or worse, when they will actually receive their money.  Many of them were notified that they would have answers by the end of the first quarter, but now that we are in April, they simply can't wait any longer.  I only expect more and more Avandia Plaintiffs to seek lawsuit funding each day this drags on."  

Industry experts believe that the Avandia litigation is getting more complex based on the few articles released of late.  

In January GlaxoSmithKline agreed to take a total of a $3.4bil charge on the expected Avandia settlement.  This is an increase from the $2.4bil charge announced last summer.  The increase raises more questions as to the magnitude of the total settlement; and if Avandia will surpass Vioxx as the largest Pharmaceutical settlement in U.S. History.

Also, in February the Louisiana AG Office sued GlaxoSmithKline for civil fraud involving Avandia.  The increase in more litigation involving Avandia –and the subsequent delays- is now only hurting the people most affected by the drug.  And that is the Avandia long suffering plaintiffs and their families waiting for their settlement money.

Contact and Source:
CNJ Enterprises LLC
Chris Janish, CEO

SOURCE CNJ Enterprises LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DePuy Hip Recall & Avandia Focus of Nov. 3 Conference, HB Announces
2. GSK Regulatory Update on Avandia Following EMA and FDA Reviews
3. American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
4. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
5. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
6. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
7. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
8. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
9. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
10. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
11. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
Post Your Comments:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):